Coherus Announces Toripalimab Data at 2023 AACR-NCI-EORTC International Conference on Molecular ...

— Data demonstrate preclinical potent T cell activation and differentiated mechanism of action and enhanced clinical efficacy irrespective of PD-L1 status when administered in combination with chemotherapy —

Related Keywords

Hynes Convention Center ,Massachusetts ,United States ,United Kingdom ,China ,Boston ,Canada ,Coherus Biosciences ,Junshi Biosciences ,Theresa Lavallee ,Jodi Sievers ,Regulatory Agency ,Coherus Biosciences Inc ,Nasdaq ,Shanghai Junshi Biosciences Co Ltd ,European Medicines Agency ,International Conference On Molecular ,Drug Administration ,Exchange Commission ,Corporate Communications ,Molecular Targets ,Cancer Therapeutics ,Breakthrough Therapy ,Fast Track ,Orphan Drug ,Southeast Asia ,Surface Oncology ,Biologics License Application ,Private Securities Litigation Reform Act ,Coheru Quarterly Report ,Contact Information ,Region ,